Predictive Factors for Local Recurrence in Breast Cancer

Seminars in Radiation Oncology

Volumn 22, Issue 2, 2012, Pages 100-107

  Van der Leij, Femke ^a   Elkhuizen, Paula H M ^a   Bartelink, Harry ^a   Van de Vijver, Marc J ^a,b  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CCNB1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MKI67 PROTEIN; MYBL2 PROTEIN; ONCOPROTEIN; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

AGE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CELL PROLIFERATION; DNA REPAIR; DOUBLE STRANDED DNA BREAK; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ADULT; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MASTECTOMY; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIATION TOLERANCE; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84857524512     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2011.12.001     Document Type: Review

References (63)

1. Clarke M., Collins R., Darby S., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005, 366:2087-2106.
2. Bartelink H., Horiot J.C., Poortmans P.M., et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-Year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 2007, 25:3259-3265.
3. van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.
4. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
5. Wang Y., Klijn J.G., Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
6. Liu R., Wang X., Chen G.Y., et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007, 356:217-226.
7. van 't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
8. Buyse M., Loi S., Van't Veer L., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006, 98:1183-1192.
9. Mook S., Schmidt M.K., Viale G., et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 2009, 116:295-302.
10. Mook S., van't Veer L.J., Rutgers E.J., et al. Individualization of therapy using Mammaprint: From development to the MINDACT trial. Cancer Genomics Proteomics 2007, 4:147-155.
11. Zujewski J.A., Kamin L. Trial assessing individualized options for treatment for breast cancer: The TAILORx trial. Future Oncol 2008, 4:603-610.
12. Kreike B., Halfwerk H., Armstrong N., et al. Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients. Clin Cancer Res 2009, 15:4181-4190.
13. Nuyten D.S., Kreike B., Hart A.A., et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 2006, 8:R62.
14. Mamounas E.P., Tang G., Fisher B., et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: Results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010, 28:1677-1683.
15. Fourquet A., Campana F., Zafrani B., et al. Prognostic factors of breast recurrence in the conservative management of early breast cancer: A 25-year follow-up. Int J Radiat Oncol Biol Phys 1989, 17:719-725.
16. Veronesi U., Marubini E., Del Vecchio M., et al. Local recurrences and distant metastases after conservative breast cancer treatments: Partly independent events. J Natl Cancer Inst 1995, 87:19-27.
17. Elkhuizen P.H., van de Vijver M.J., Hermans J., et al. Local recurrence after breast-conserving therapy for invasive breast cancer: High incidence in young patients and association with poor survival. Int J Radiat Oncol Biol Phys 1998, 40:859-867.
18. Fowble B.L., Schultz D.J., Overmoyer B., et al. The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys 1994, 30:23-33.
19. Borger J., Kemperman H., Hart A., et al. Risk factors in breast-conservation therapy. J Clin Oncol 1994, 12:653-660.
20. Schnitt S.J., Abner A., Gelman R., et al. The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer 1994, 74:1746-1751.
21. Park C.C., Mitsumori M., Nixon A., et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: Influence of margin status and systemic therapy on local recurrence. J Clin Oncol 2000, 18:1668-1675.
22. Jones H.A., Antonini N., Hart A.A., et al. Impact of pathological characteristics on local relapse after breast-conserving therapy: A subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol 2009, 27:4939-4947.
23. Werkhoven E., Hart G., Tinteren H., et al. Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-10882 boost versus no boost trial. Radiother Oncol 2011, 100:101-107.
24. Gage I., Schnitt S.J., Nixon A.J., et al. Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy. Cancer 1996, 78:1921-1928.
25. Esteva F.J., Hortobagyi G.N. Prognostic molecular markers in early breast cancer. Breast Cancer Res 2004, 6:109-118.
26. Payne S.J., Bowen R.L., Jones J.L., et al. Predictive markers in breast cancer-The present. Histopathology 2008, 52:82-90.
27. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
28. Ahlin C., Aaltonen K., Amini R.M., et al. Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values?. Histopathology 2007, 51:491-498.
29. Colozza M., Azambuja E., Cardoso F., et al. Proliferative markers as prognostic and predictive tools in early breast cancer: Where are we now?. Ann Oncol 2005, 16:1723-1739.
30. Jung S.Y., Han W., Lee J.W., et al. Ki-67 expression gives additional prognostic information on St. Gallen 2007 and adjuvant! Online risk categories in early breast cancer. Ann Surg Oncol 2009, 16:1112-1121.
31. de Azambuja E., Cardoso F., de Castro G., et al. Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007, 96:1504-1513.
32. Elkhuizen P.H., Voogd A.C., van den Broek L.C., et al. Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: A case-control study of histological factors and alterations in oncogene expression. Int J Radiat Oncol Biol Phys 1999, 45:73-83.
33. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003, 100:8418-8423.
34. Perou C.M., Jeffrey S.S., van de Rijn M., et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 1999, 96:9212-9217.
35. Dawood S., Hu R., Homes M.D., et al. Defining breast cancer prognosis based on molecular phenotypes: Results from a large cohort study. Breast Cancer Res Treat 2011, 126:185-192.
36. Nguyen P.L., Taghian A.G., Katz M.S., et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008, 26:2373-2378.
37. Voduc K.D., Cheang M.C., Tyldesley S., et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010, 28:1684-1691.
38. Kiess A.P., McArthur H.L., Mahoney K., et al. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer. Cancer 2011 Sep 1, [Epub ahead of print].
39. Chang H.Y., Nuyten D.S., Sneddon J.B., et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 2005, 102:3738-3743.
40. Chi J.T., Wang Z., Nuyten D.S., et al. Gene expression programs in response to hypoxia: Cell type specificity and prognostic significance in human cancers. PLoS Med 2006, 3:e47.
41. Nielsen H.M., Overgaard M., Grau C., et al. Loco-regional recurrence after mastectomy in high-risk breast cancer-Risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials. Radiother Oncol 2006, 79:147-155.
42. Jagsi R., Raad R.A., Goldberg S., et al. Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: Implications for postmastectomy radiation. Int J Radiat Oncol Biol Phys 2005, 62:1035-1039.
43. de Bock G.H., van der Hage J.A., Putter H., et al. Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: Long-term results of European organisation for research and treatment of cancer studies. Eur J Cancer 2006, 42:351-356.
44. Fredholm H., Eaker S., Frisell J., et al. Breast cancer in young women: Poor survival despite intensive treatment. PLoS ONE 2009, 4:e7695.
45. Willner J., Kiricuta I.C., Kölbl O. Locoregional recurrence of breast cancer following mastectomy: Always a fatal event?. Results of univariate and multivariate analysis. Int J Radiat Oncol Biol Phys 1997, 37:853-863.
46. Taghian A.G., Jeong J.H., Mamounas E.P., et al. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: Results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol 2006, 24:3927-3932.
47. de la Rochefordiere A., Asselain B., Campana F., et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet 1993, 341:1039-1043.
48. Kyndi M., Sørensen F.B., Knudsen H., et al. The Danish breast cancer cooperative group: Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer. J Clin Oncol 2008, 26:1419-1426.
49. Kunkler I.H., Canney P., van Tienhoven G., et al. Elucidating the role of chest wall irradiation in "intermediate-risk" breast cancer: The MRC/EORTC SUPREMO trial. Clin Oncol R (Coll Radiol) 2008, 20:31-34.
50. Cheng S.H., Horng C.F., West M., et al. Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol 2006, 24:4594-4602.
51. Voogd A.C., Nielsen M., Peterse J.L., et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: Pooled results of two large European randomized trials. J Clin Oncol 2001, 19:1688-1697.
52. Garcia-Etienne C.A., Barile M., Gentilini O.D., et al. Breast-conserving surgery in BRCA1/2 mutation carriers: Are we approaching an answer?. Ann Surg Oncol 2009, 16:3380-3387.
53. Robson M., Levin D., Federici M., et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 1999, 91:2112-2117.
54. Haffty B.G., Harrold E., Khan A.J., et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 2002, 359:1471-1477.
55. Pierce L.J., Levin A.M., Rebbeck T.R., et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006, 24:2437-2443.
56. Pierce L.J., Strawderman M., Narod S.A., et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 2000, 18:3360-3369.
57. Shanley S., McReynolds K., Ardern-Jones A., et al. Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clin Cancer Res 2006, 12:7025-7032.
58. Amundson S.A., Do K.T., Vinikoor L.C., et al. Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute anticancer drug screen. Cancer Res 2008, 68:415-424.
59. Torres-Roca J.F., Eschrich S., Zhao H., et al. Prediction of radiation sensitivity using a gene expression classifier. Cancer Res 2005, 65:7169-7176.
60. Rødningen O.K., Børresen-Dale A.L., Alsner J., et al. Radiation-induced gene expression in human subcutaneous fibroblasts is predictive of radiation-induced fibrosis. Radiother Oncol 2008, 86:314-320.
61. Russell N.S., Grummels A., Hart A.A., et al. Low predictive value of intrinsic fibroblast radiosensitivity for fibrosis development following radiotherapy for breast cancer. Int J Radiat Biol 1998, 73:661-670.
62. Peacock J., Ashton A., Bliss J., et al. Cellular radiosensitivity and complication risk after curative radiotherapy. Radiother Oncol 2000, 55:173-178.
63. Helland A., Johnsen H., Frøyland C., et al. Radiation-induced effects on gene expression: An in vivo study on breast cancer. Radiother Oncol 2006, 80:230-235.